The Silicon Review
Our vision embodies uncompromising quality, exceptional service, and innovative solutions.
Cancer is a ruthless disease known to mankind; our own body cells turning against us and going rogue, destroying everything that comes in its way. Cancer causes millions of death every year and we still have a long way to go to find a permanent cure.
The number of people diagnosed with tumors, especially malignant ones, is constantly increasing. There is also a rise in mortality rate due to delayed diagnosis and wrong treatment. Hence, a proper cancer diagnosis is very important.
NeoGenomics Laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. The firm serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. NeoGenomics has a network of CAP-accredited, CLIA-licensed facilities across the U.S., but works hard to maintain easy access and all the efficiencies of a smaller operation.
Deep Dive into NeoGenomics
NeoGenomics Laboratories is comprised of a national team of experts in developing and delivering laboratory diagnostic and clinical trial services with a focus on cancer. Its staff physicians, scientists, laboratory professionals, client services representatives, and salespeople team up with its clients. Together, they work to solve the medical, scientific, and logistical challenges of making precise diagnoses, aiding in bringing new therapies to market and finding the unique hallmarks of each patient’s disease that point the way to proper treatment.
The company provides expert bone marrow and surgical pathology consults; cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with the largest menu of technical-only services available; 10-color flow cytometry; histology supported by an extensive IHC antibody library; and >160 molecular oncology tests comprising the most comprehensive combination of multi-method tumor profiles and targeted biomarker tests in the industry.
NeoGenomics’ technical-only testing programs feature on-demand or live training is available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. Its Pharma Services division offers all of these methodologies along with other technology platforms to provide laboratory services that meet the rapidly evolving needs of its clients. Through NeoGenomics’ differentiators of expertise, flexibility, and scalability it partners with its clients to develop better, more effective drugs.
The Importance of NeoGenomics’ Work
People with cancer need more options, and the firm believes precision medicine is a critical component in controlling cancer. With all testing methodologies in one laboratory system, NeoGenomics has the ability to interrogate blood-based cancer or solid tumor by as many means necessary to reveal biomarkers that expose that disease’s susceptibilities to standard or novel therapies. NeoGenomics’ extremely fast test development cycle means it is highly responsive to guideline changes and new therapy options. Design of NeoGenomics’ new tests always involves a balance of convention and innovation so costs are reduced and results become available promptly.
It all comes back to the patients. Time and results mean everything to the patients, and NeoGenomics keeps that first in its minds.
Pharma Services Offered
With NeoGenomics' acquisition of Clarient, NeoGenomics’ Pharma Services division now offers a wider range of service offerings and provide an even higher level of support to its clients. Whether you need a custom assay developed or would like to use one of its clinically validated tests, the firm can help advance your clinical trial.
NeoGenomics Pharma Services has developed tools to help its clients with their clinical trial and research laboratory service needs. Whether you need custom biomarker development or would like to use an assay from its robust clinical menu, the firm can help. With over a decade of experience, NeoGenomics is one of the fastest growing and innovative companies in the biotech space.
Personalized medicine is an evolving field in which treatments are tailored to the individual patient. The FDA requires a companion diagnostic test (CDx) if a new drug works on a specific genetic or biological target that is present in some, but not all, patients with certain cancer. The CDx identifies which patients would benefit from the use of, or who could be harmed by the use of a certain drug for treatment of their disease.
NeoGenomics' Pharma Services offers a wide variety of assays utilizing FDA-Approved and FDA-Cleared assays and instruments on multiple modalities to help accelerate your drug development. All tests listed have been clinically validated in its laboratories and are available for research or clinical use.
Knowing the Key Executive
Douglas M. VanOort, Chairman of the Board of Directors and CEO: VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of NeoGenomics since October 28, 2009. For seven months prior to October 2009, he served as Chairman of the Board of Directors, Executive Chairman, and Interim Chief Executive Officer. Prior to joining NeoGenomics, Mr. VanOort was a General Partner with a private equity firm and a Founding Managing Partner of a venture capital firm. From 1982 through 1999, Mr. VanOort served in various positions at Corning Incorporated and at its spin-off company, Quest Diagnostics, Inc. During the period from 1995 through 1999, he served as the Senior Vice President Operations for Quest Diagnostics, Inc. which was then a $1.5 billion newly formed NYSE-traded Company. During the period of 1989 to 1995, he held senior executive positions at Corning Life Sciences, Inc., including Executive Vice President. Corning Life Sciences Inc. had revenues of approximately $2 billion and was spun-off in a public transaction to create both Quest Diagnostics and Covance, Inc. From 1982 to 1989, Mr. VanOort served in various executive positions at Corning Incorporated, including Director of Mergers & Acquisitions. Mr. VanOort currently serves as a member of the Board of Directors of several privately-held companies and is a principal owner of a privately-held retail hardware store chain. Mr. VanOort is a graduate of Bentley University.